The record
The 2024 Journal of Clinical Oncology Sister Study analysis (PMID 38748950) reported a hazard ratio of 1.40 (95% CI 1.04-1.89) for genital talc use and ovarian cancer under one bias-correction scenario (25%/10% exposure reassignment); across correction scenarios the estimates ranged from 1.17 to 3.34.
Claim scope
The published bias-corrected estimates and their scenario structure.
What this source does not establish
The 1.40 figure is one bias-correction scenario, not the study's single headline result, and the 1.17-3.34 range spans correction scenarios — not exposure levels or dose categories.
Limitations
Describe the scenario structure explicitly whenever the 1.40 or the range is cited.
Source
Pmid — 38748950